Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 3553

Technology As A Force For Good In People’s Lives — Dr. Emre Ozcan, PhD, VP, Global Head of Digital Health & Walid Mehanna, Group Data Officer And Senior Vice President, Merck KGaA, Darmstadt, Germany.

EPISODE DISCLAIMER — At any time during this episode when anyone says Merck, in any context, it shall always be referring to Merck KGaA, Darmstadt, Germany.

Dr. Emre Ozcan, Ph.D. is VP, Global Head of Digital Health, at Merck KGaA, Darmstadt, Germany (https://www.emdgroup.com/en), where he brings 15+ years experience in biopharma, med-tech and healthcare consulting with experience across strategy, research, marketing, and operations in several therapeutic areas. In his current role, he holds the accountability for the design and end-to-end delivery of digital health solutions to support Merck KGaA, Darmstadt, Germany franchise strategies and shape the architecture of the offering “around the drug” including devices and diagnostics.

Continue reading “Dr. Emre Ozcan & Walid Mehanna — Merck KGaA, Darmstadt, Germany — Tech As A Force For Good In Health” | >

EPISODE DISCLAIMER — The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent.

Dr. Devi SenGupta, MD, MPhil, is Executive Director of Clinical Development at Gilead Sciences (https://www.gilead.com/), where she leads the company’s HIV cure development program and during her time at the company has led multiple HIV treatment and cure studies. As head of the HIV cure program, she provides strategic direction for cross-functional internal teams and external multi-stakeholder collaborations developing combination approaches aimed at achieving long-term HIV remission.

Before joining Gilead in 2015, Dr. SenGupta was a physician scientist leading translational HIV immunology research as an Assistant Professor at the University of California, San Francisco (UCSF). Her NIH-funded program focused on identifying novel strategies to enhance cellular immunity against HIV.

Dr. SenGupta received her Bachelor of Arts in psychology and biology at Harvard University, MPhil. in neuropsychology at Cambridge University, UK, and MD at the University of Washington School of Medicine. She completed her internal medicine residency at Johns Hopkins Hospital and infectious diseases fellowship at UCSF.

Continue reading “Dr. Devi SenGupta, MD, MPhil — Executive Director of Clinical Development, Gilead Sciences” | >

Summary: For the first time, Google Quantum AI has observed the peculiar behavior of non-Abelian anyons, particles with the potential to revolutionize quantum computing by making operations more resistant to noise.

Non-Abelian anyons have the unique feature of retaining a sort of memory, allowing us to determine when they have been exchanged, even though they are identical.

The team successfully used these anyons to perform quantum computations, opening a new path towards topological quantum computation. This significant discovery could be instrumental in the future of fault-tolerant topological quantum computing.

Read more | >

OTTAWA, May 15 (Reuters) — Automaker Stellantis (STLAM.MI) has stopped all construction at a more-than C$5 billion ($3.74 billion) electric vehicle battery manufacturing plant in Windsor, Canada, over a disagreement with the federal government about subsidies, a spokesperson for the company said on Monday.

“Effective immediately, all construction related to the battery module production on the Windsor site has stopped,” the spokesperson said.

Canada’s industry ministry did not immediately respond to a request for comment.

Read more | >

Kathy Lueders, the most recent top human spaceflight official at NASA, has joined Elon Musk’s SpaceX after retiring from the agency a couple of weeks ago, CNBC has learned.

Lueders’ role will be general manager, and she will work out of the company’s “Starbase” facility in Texas, reporting directly to SpaceX president and COO Gwynne Shotwell, people familiar with the matter told CNBC.

It’s a key hire for SpaceX as the company aims to make its massive Starship rocket safe to fly people in the coming years. Lueders, a respected expert in the sector, is already familiar with the company’s human spaceflight work to date.

Read more | >

Dibaryons are subatomic particles composed of two baryons. Their formation, which occurs through interactions between baryons, is fundamental in big-bang nucleosynthesis, nuclear reactions including those happening within stars, and bridges the gap between nuclear physics, cosmology, and astrophysics. Fascinatingly, the strong force, responsible for the formation and the majority of the mass of nuclei, facilitates the formation of a plethora of different dibaryons with diverse quark combinations.

Nevertheless, these dibaryons are not commonly observed — the deuteron is currently the only known stable dibaryon.

To resolve this apparent dichotomy, it is essential to investigate dibaryons and baryon-baryon interactions at the fundamental level of strong interactions. In a recent publication in Physical Review Letters.

Read more | >

Northwestern investigators have demonstrated that fine-tuning DNA interaction strength can improve colloidal crystal engineering to enhance their use in creating an array of functional nanomaterials, according to a recent study published in ACS Nano.

Chad Mirkin, Ph.D., professor of Medicine in the Division of Hematology and Oncology, the George B. Rathmann Professor of Chemistry at Northwestern’s Weinberg College of Arts and Sciences, and director of the International Institute for Nanotechnology, was senior author of the study.

Colloidal crystal engineering with DNA involves modifying nanoparticles into programmable atom equivalents, or “PAEs,” which are used to form that can then be used for designing programmable, synthetic DNA sequences.

Read more | >